A method for determining MSC tissue distribution
Through real-time fluorescence quantitative PCR technology, the CD105 gene was amplified by differential design of specific primers in human and mouse genes, which solved the problem that the number of mesenchymal stem cells in MSC tissues in the existing technology is unable to accurately measure the number of mesenchymal stem cells in MSC tissues, and achieved absolute quantitative detection of cells , supports pharmacokinetic research and clinical protocol design.
Patent Information
- Application Number
- CN202110311237.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-03-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-03-24
AI Technical Summary
The prior art cannot accurately measure the number of mesenchymal stem cells in MSC tissues, and only qualitative and relatively quantitative traceability can be achieved.
Real-time fluorescence quantitative PCR technology is used to design differential specific primers for human and mouse genes, and amplify the CD105 gene, and achieve absolute quantitative detection of human mesenchymal stem cells.
Accurate quantitative detection of mesenchymal stem cells in tissues can track the metabolic status and colonization rate of cells in the body, providing methodological support for pharmacokinetic research and clinical protocol design.
Smart Images

Figure CN113046423B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical detection, and in particular relates to a method for quantitatively determining MSC tissue distribution. Background Art
[0002] Mesenchymal stem cells are a type of pluripotent stem cells derived from the mesoderm, with excellent self-renewal and multidirectional differentiation capabilities. Due to their wide range of sources, multidirectional differentiation potential and strong homing ability, they have been well used in clinical treatment. The application of stem cells as drugs requires the use of animals for preclinical research, especially the study of drug level effectiveness and drug metabolism levels. At present, the use of isotope tracing, small animal living imaging, ordinary PCR and other technologies can achieve in vivo or in vitro cell tracing, but these tracers only stay at the qualitative and relative quantitative level of cells, and cannot achieve accurate quantification of cell content in tissues. Summary of the invention
[0003] In view of the problem that the number of mesenchymal stem cells in tissues cannot be accurately quantified in the prior art, the present invention provides a method for quantitatively determining the tissue distribution of MSCs by using real-time fluorescence quantitative PCR.
[0004] To achieve the above purpose, the present invention adopts the following technical solution.
[0005] A method for determining MSC tissue distribution comprises the following steps:
[0006] (1) Human mesenchymal stem cells are infused into experimental mice, and samples of organs or tissues to be monitored are taken at regular intervals to extract DNA samples;
[0007] (2) Extract DNA from a certain number of human mesenchymal stem cells and dilute them into a series of DNA solutions;
[0008] (3) using the sequences shown in SEQ ID NOs: 1 and 2 as primers, and using the DNA sample in step (1) and the DNA solution in step (2) as templates to perform real-time fluorescence quantitative PCR;
[0009] (4) Prepare a standard curve using the CT values of the DNA solutions of different concentrations in step (2) and calculate the amount of DNA sample in step (1).
[0010] The experimental mice are selected from mice, rats or nude mice.
[0011] The source of the human mesenchymal stem cells is not limited, but is preferably placenta, umbilical cord, bone marrow, fat or blood.
[0012] Preferably, the flow cytometric detection of the human mesenchymal stem cells shows that the positive rates of CD73, CD105, CD44, and CD90 are all above 98%, and the negative rates of CD34, CD45, and HLA-DR are below 0.2%.
[0013] The real-time fluorescence quantitative PCR uses SYBR Green as the fluorescent dye.
[0014] The present invention has the following advantages:
[0015] Based on the gene difference between humans and mice, the present invention selects the surface marker gene CD105 specific to mesenchymal stem cells as the target gene for amplification. From the CD105 gene, a CD105 fragment with severe mouse deletion but intact human sequence is selected for primer design, which is used as a primer for real-time fluorescence quantitative PCR amplification, with high specificity and low detection limit.
[0016] The method of the present invention uses real-time fluorescence quantitative PCR technology to replace the ordinary PCR technology, and designs human gene-specific primers through human-mouse gene differences to perform real-time fluorescence quantitative PCR, thereby achieving absolute quantification of the mesenchymal stem cell colonization rate in tissues. The designed primers have high specificity, and the quantification of human mesenchymal stem cells is more accurate. The present invention can track the absolute quantification of mesenchymal stem cells in tissues over time in various tissues in the body and the colonization rate in various tissues, providing methodological support for pharmacokinetic research in stem cell drug development, and providing a reference basis for the design of administration routes and dosages in clinical programs. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The results of culture and phenotypic identification of mesenchymal stem cells;
[0018] Figure 2 is the melting curve obtained for each primer pair;
[0019] Figure 3 The standard curve obtained for each primer pair;
[0020] Figure 4 is the melting curve of the specificity test of primer pair 1;
[0021] Figure 5 is the content of mesenchymal stem cells in different tissues. DETAILED DESCRIPTION
[0022] The present invention will be further described below in conjunction with embodiments and drawings, but the present invention is not limited by the following embodiments.
[0023] Example 1 Determination of detection primers
[0024] (1) Figure 11×10 human umbilical cord mesenchymal stem cells with positive rates of CD73, CD105, CD44, and CD90 above 98% and negative rates of CD34, CD45, and HLA-DR below 0.2% as shown in the flow cytometry results. 7 DNA was extracted using a blood / cell / tissue genomic DNA extraction kit (DP304, Tiangen Biochemical Technology (Beijing) Co., Ltd.), the total amount of DNA was calculated, and then diluted in half 9 times to obtain 10 series of DNA standard solutions;
[0025] (2) Three pairs of primers were designed and synthesized based on SEQ ID NO: 7-9 as the target sequences:
[0026]
[0027] Real-time fluorescence quantitative PCR was performed using the DNA standard solution in step (1) as a template. The reaction system was as follows:
[0028]
[0029] The amplification reaction is as follows:
[0030]
[0031] The reaction for obtaining the melting curve was as follows: 95°C, 15 min, pre-denaturation; 60°C, 60 s, annealing; 0.15°C / s to 95°C, signal acquisition every 5 s;
[0032] (3) The melting curves of the three primer pairs are as follows Figure 2 As shown (a is primer pair 1, b is primer pair 2, and c is primer pair 3), a series of DNA solutions with different concentrations are converted into cell numbers according to the DNA mass, and a standard curve is prepared with the LOG value of the number of mesenchymal stem cells as the horizontal axis and the CT value as the vertical axis, as shown in FIG. Figure 3 shown.
[0033] according to Figure 2 and Figure 3 Yes, the detection limit of primer 1 is below 0.195ng, and there is no non-specific amplification within the detection concentration. Primer 2 can detect about 0.781ng of DNA, and primer dimers appear when the concentration is lower than this. Primer 3 can only detect 12.5ng of DNA, and primer dimers appear when the concentration is lower than this. It can be seen that the detection line of the first pair of primers for CD105 is lower.
[0034] Example 2 Repeatability test
[0035] The first pair of primers was tested for repeatability. Ten series of DNA standard solutions in Example 1 were taken and amplification experiments were performed according to the method in Example 1. The obtained melting curves were as follows: Figure 4 As shown in the figure, the melting curve shows that primer pair 1 has no non-specific amplification and can be used to evaluate the method. The coefficient of variation (CV) is calculated based on the Ct value of each standard solution. When the amount of DNA changes from 0.19 ng to 100 ng, the coefficient of variation ranges from 0.97% to 2.76%, which is less than 3%, and can be used for subsequent quantitative detection.
[0036] Example 3 Quantitative detection of tissue distribution of mesenchymal stem cells
[0037] (1) Figure 1 The mesenchymal stem cells derived from human umbilical cord with positive rates of CD73, CD105, CD44, and CD90 above 98% and negative rates of CD34, CD45, and HLA-DR below 0.2% were infused, and the cell density in the injection solution was adjusted to 1×10 7 cells / mL, BALB / c-nude mice (female mice) were used as test subjects, and the tail vein injection was performed, and the injection volume per mouse was 200 μL, for a total of 15 mice;
[0038] At 24h, 48h, 72h, 96h, and 120h after injection, three nude mice were randomly selected at each time point and anesthetized and then killed by cervical stenosis. The heart, liver, spleen, lung, and kidney tissues were removed, the blood stains were washed away, the water was absorbed, and the mice were weighed and frozen at -80℃.
[0039] After all sampling was completed, DNA was extracted using a blood / cell / tissue genomic DNA extraction kit (DP304, Tiangen Biochemical Technology (Beijing) Co., Ltd.);
[0040] (2) using the sequences shown in SEQ ID NO: 1-2 as primers, perform qPCR according to the method in Example 1;
[0041] (3) According to the standard curve y=-3.3853x+32.291 (R 2 =0..995) to calculate the amount of DNA sample in step (1), and then calculate the number of mesenchymal stem cells per unit tissue based on the sample weight used for DNA extraction. The test results are shown in the attached figure. Figure 5 shown. Sequence Listing <110> Shandong Qilu Cell Therapy Engineering Technology Co., Ltd., Yinfeng Bioengineering Group Co., Ltd. <120> A method for determining MSC tissue distribution <130> 20210121 <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Forward1 <400> 1 ctcccttgga tcagtggcca cactg 25 <210> 2 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Reverse1 <400> 2 gcgattctca ggctcttcta t 21 <210> 3 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Forward2 <400> 3 gggcgacaga gcgagactcc gcctc 25 <210> 4 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse2 <400> 4 cctcccaggt tcaagcaa 18 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Forward3 <400> 5 gtggcgggca cctgtaatcc c 21 <210> 6 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Reverse3 <400> 6 gccctgtgga gttgcctga 19 <210> 7 <211> 183 <212> DNA <213> Homo sapiens <400> 7 gggcgacaga gcgagactcc gcctcaaaga aaaaaaaaga aaaaaaaaa aagccaacct 60 ggccaacatg gtgaaactcc atctctagta aaaatacaaa aaattagcca tgcgtcgtgg 120 tgggcacctg cagttccagc tactcgggag gctgaggcag gagaattgct tgaacctggg 180 Aug 183 <210> 8 <211> 144 <212> DNA <213> Homo sapiens <400> 8 ctcccttgga tcagtggcca cactgttggt gaagcacctc tgtgtgagct tgggcaaggt 60 acatcagcct ctctgagcct cattttctc atctgcacat gggaacaatg ggagtagcta 120 atcatagaag agcctgagaa tcgc 144 <210> 9 <211> 175 <212> DNA <213> Homo sapiens <400> 9 gtggcgggca cctgtaatcc cagctacttg ggaggctgag gtaggagaat ggcatgaacc 60 cgggaggcgg agcttgcagt gagctgagat cgcaccactg cactccagcc tgggcgacag 120 agcgagactc cgtctcaaaa aaaaaaaaa agagagtcag gcaactccac agggc 175
Claims
1. A method for determining MSC tissue distribution, characterized in that: The following steps are involved: (1) Human mesenchymal stem cells are infused into experimental mice, and samples of organs or tissues to be monitored are taken at regular intervals to extract DNA samples; (2) Extract DNA from a certain number of human mesenchymal stem cells and dilute them into a series of DNA solutions; (3) using the sequences shown in SEQ ID NOs: 1 and 2 as primers and the DNA sample in step (1) and the DNA solution in step (2) as templates to perform real-time fluorescence quantitative PCR; (4) Convert the DNA mass of the DNA solution of the series of concentrations in step (2) into the number of cells, prepare a standard curve with the LOG value of the number of mesenchymal stem cells as the horizontal axis and the CT value as the vertical axis, calculate the number of DNA samples in step (1), and then calculate the number of mesenchymal stem cells per unit tissue based on the sample weight used for DNA extraction; The source of the human mesenchymal stem cells is selected from placenta, umbilical cord, bone marrow, fat or blood.
2. The method according to claim 1, characterized in that The experimental mice are selected from mice or rats.
3. The method according to claim 1, characterized in that The flow cytometric detection of the human mesenchymal stem cells showed that the positive rates of CD73, CD105, CD44, and CD90 were all above 98%, and the negative rates of CD34, CD45, and HLA-DR were below 0.2%.
4. The method according to claim 1, characterized in that The real-time fluorescence quantitative PCR uses SYBR Green as the fluorescent dye.
